Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Infectious Diseases
Volume 2018, Article ID 2658083, 4 pages
https://doi.org/10.1155/2018/2658083
Case Report

Pulmonary Mucormycosis in Chronic Lymphocytic Leukemia and Neutropenia

Department of Medicine, Reading Health System, 420 S. Fifth Avenue, West Reading, PA 19611, USA

Correspondence should be addressed to Izza Mir; gro.htlaehgnidaer@rim.azzi

Received 14 September 2017; Revised 1 January 2018; Accepted 15 January 2018; Published 19 February 2018

Academic Editor: Sinésio Talhari

Copyright © 2018 Izza Mir et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. M. Roden, T. E. Zaoutis, W. L. Buchanan et al., “Epidemiology and outcome of zygomycosis: a review of 929 reported cases,” Clinical Infectious Diseases, vol. 41, no. 5, pp. 634–653, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Petrikkos, A. Skiada, O. Lortholary, E. Roilides, T. J. Walsh, and D. P. Kontoyiannis, “Epidemiology and clinical manifestations of mucormycosis,” Clinical Infectious Diseases, vol. 54, no. 1, pp. S23–S34, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Samarei, N. Gharebaghi, and S. Zayer, “Evaluation of 30 cases of mucormycosis at a university hospital in Iran,” Mycoses, vol. 60, no. 7, pp. 426–432, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Y. W. Lee, S. B. Mossad, and K. A. Adal, “Pulmonary mucormycosis the last 30 years,” Archives of Internal Medicine, vol. 159, no. 12, pp. 1301–1309, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. T. J. Walsh, M. N. Gamaletsou, M. R. McGinnis, R. T. Hayden, and D. P. Kontoyiannis, “Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis),” Clinical Infectious Diseases, vol. 54, no. 1, pp. S55–S60, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Chamilos, E. M. Marom, R. E. Lewis, M. S. Lionakis, and D. P. Kontoyiannis, “Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer,” Clinical Infectious Diseases, vol. 41, no. 1, pp. 60–66, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Lin, T. Moua, and A. H. Limper, “Pulmonary mucormycosis: clinical features and outcomes,” Infection, vol. 45, no. 4, pp. 443–448, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. R. G. Munoz, A. Izquierdo-Gil, A. Munoz, V. Roldan-Galiacho, P. Rabasa, and C. Panizo, “Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab,” Annals of Hematology, vol. 93, no. 11, pp. 1879–1887, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Nosari, “Infectious complications in chronic lymphocytic leukemia,” Mediterranean Journal of Hematology and Infectious Diseases, vol. 4, no. 1, p. e2012070, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Bourcier, P. M. Heudes, F. Morio et al., “Prevalence of the reversed halo sign in neutropenic patients compared with non-neutropenic patients: data from a single-centre study involving 27 patients with pulmonary mucormycosis (2003–2016),” Mycoses, vol. 60, no. 8, pp. 526–533, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. R. A. Murphy and W. T. Miller Jr., “Pulmonary mucormycosis,” Seminars in Roentgenology, vol. 31, no. 1, pp. 83–87, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. S. P. Hammond, R. Bialek, D. A. Milner, E. M. Petschnigg, L. R. Baden, and F. M. Marty, “Molecular methods to improve diagnosis and indentification of mucormycosis,” Journal of Clinical Microbiology, vol. 49, no. 6, pp. 2151–2153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Tedder, J. A. Spratt, M. P. Anstadt, S. S. Hegde, S. D. Tedder, and J. E. Lowe, “Pulmonary mucormycosis: results of medical and surgical therapy,” Annals of Thoracic Surgery, vol. 57, no. 4, pp. 1044–1050, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Van Burik, R. S. Hare, H. F. Solomon, M. L. Corrado, and D. P. Kontoyiannis, “Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases,” Clinical Infectious Diseases, vol. 42, no. 7, pp. e61–e65, 2006. View at Publisher · View at Google Scholar
  15. B. Spellberg, A. Ibrahim, E. Roilides et al., “Combination therapy for mucormycosis: why, what, and how?” Clinical Infectious Diseases, vol. 54, no. 1, pp. S73–S78, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Chamilos, R. E. Lewis, and D. P. Kontoyiannis, “Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis,” Clinical Infectious Diseases, vol. 47, no. 4, pp. 503–509, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. O. A. Cornely, J. Maertens, D. J. Winston et al., “Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia,” New England Journal of Medicine, vol. 354, no. 4, pp. 348–359, 2007. View at Publisher · View at Google Scholar · View at Scopus